{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:30:57Z","timestamp":1768440657963,"version":"3.49.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/jcp.0b013e31829c762b","type":"journal-article","created":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T10:55:38Z","timestamp":1376736938000},"page":"766-774","source":"Crossref","is-referenced-by-count":16,"title":["Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1097","volume":"33","author":[{"given":"Joaquin","family":"Fuentes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Danckaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Cardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanasagabi","family":"Puvanendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Berquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"De Bruyckere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Quail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145703003973","article-title":"Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.","volume":"7","author":"Biederman","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1542\/peds.2005-0386","article-title":"Worse quality of life for children with newly diagnosed attention-deficithyperactivity disorder, compared with asthmatic and healthy children.","volume":"116","author":"Escobar","year":"2005","journal-title":"Pediatrics"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00019053-200321170-00002","article-title":"Economic implications of attention-deficit hyperactivity disorder for healthcare systems.","volume":"21","author":"Leibson","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/11537450-000000000-00000","article-title":"The impact of medications on quality of life in attention-deficit hyperactivity disorder.","volume":"24","author":"Coghill","year":"2010","journal-title":"CNS Drugs"},{"key":"R6-9-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00787-006-0549-0","article-title":"Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.","volume":"15","author":"Banaschewski","year":"2006","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-244X-11-176","article-title":"Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta analysis.","volume":"10","author":"Hanwella","year":"2011","journal-title":"BMC Psychiatry"},{"key":"R9-9-20210128","first-page":"5","article-title":"Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.","volume":"19","author":"Hazell","year":"2011","journal-title":"J Atten Disord"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1185\/030079906X167309","article-title":"A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficithyperactivity disorder (ADHD).","volume":"23","author":"Prasad","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/cap.2008.0109","article-title":"Evaluation of patients and parents quality of life in a randomized placebo-controlled atomoxetine study in attention-deficithyperactivity disorder.","volume":"19","author":"Escobar","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R12-9-20210128","first-page":"39","article-title":"Does switching from oral extended release methylphenidate to methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficithyperactivity disorder Child Adolesc Psychiatry Ment Health.","volume":"3","author":"Bukstein","year":"2009","journal-title":""},{"key":"R13-9-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1684\/epd.2009.0278","article-title":"Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: an open-label study using an osmotic-controlled release oral delivery system.","volume":"11","author":"Yoo","year":"2009","journal-title":"Epileptic Disord"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00005650-199808000-00011","article-title":"A taxonomy of adolescent health: development of the adolescent health profile-types.","volume":"36","author":"Riley","year":"1998","journal-title":"Med Care"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1542\/peds.91.2.430","article-title":"Adolescent health status measurement: development of the Child Health and Illness Profile.","volume":"91","author":"Starfield","year":"1993","journal-title":"Pediatrics"},{"key":"R16-9-20210128","first-page":"232","article-title":"The Child Report Form of the CHIP-Child Edition: reliability and validity.","volume":"42","author":"Riley","year":"2004","journal-title":"Med Care"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.mlr.0000114910.46921.73","article-title":"The parent report form of the CHIP-Child Edition: reliability and validity.","volume":"42","author":"Riley","year":"2004","journal-title":"Med Care"},{"key":"R18-9-20210128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/01.MLR.0000088460.42155.65","article-title":"Validity of the Spanish version of the Child Health and Illness Profile-Adolescent Edition (CHIP-AE).","volume":"41","author":"Rajmil","year":"2003","journal-title":"Med Care"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00787-009-0031-x","article-title":"Atomoxetine improves patient and family coping in attention deficithyperactivity disorder: a randomized, double-blind, placebo controlled study in Swedish children and adolescents.","volume":"18","author":"Svanborg","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","article-title":"Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficithyperactivity disorder and comorbid oppositional defiant disorder: a placebo controlled Italian study.","volume":"19","author":"DellAgnello","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/JCP.0b013e3181d21763","article-title":"Quality of life and attention-deficithyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.","volume":"30","author":"Escobar","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R22-9-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12402-011-0066-y","article-title":"Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials.","volume":"2","author":"Schacht","year":"2011","journal-title":"Atten Defic Hyperact Disord"},{"key":"R24-9-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00787-009-0046-3","article-title":"The quality of life of children with attention deficithyperactivity disorder: a systematic review.","volume":"19","author":"Danckaerts","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R25-9-20210128","first-page":"571","article-title":"Pragmatic measures in paediatric psychopharmacologyare we getting it right Eur Neuropsychopharmacol.","volume":"21","author":"Coghill","year":"2011","journal-title":""},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life.","volume":"41","author":"Norman","year":"2003","journal-title":"Medical Care"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"I63","DOI":"10.1007\/s00787-006-1009-6","article-title":"Validity of the health-related quality of life assessment in the ADORE study: parent report form or the CHIP-Child Edition.","volume":"15","author":"Riley","year":"2006","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4088\/JCP.08m04709pur","article-title":"Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficithyperactivity disorder.","volume":"71","author":"Weiss","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R29-9-20210128","first-page":"13","article-title":"Real-world data on: attention deficit hyperactivity disorder medication side effects.","volume":"7","author":"Cascade","year":"2010","journal-title":"Psychiatry (Edgmont)"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00787-009-0056-1","article-title":"Treating attention-deficithyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.","volume":"19","author":"Buitelaar","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31829c762b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T19:59:45Z","timestamp":1715889585000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201312000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31829c762b","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}